Supply and Licence Agreement heralds way for Personalised Cancer Treatments

BioNTech Cell & Gene Therapies GmbH has reached a commercial agreement with Takara Bio for the use of certain patents relating to its RetroNectin® reagent, which also covers reliable supplies of the product.

Patents licensed to the Mainz-based German company are based on Takara Bio’s proprietary RetroNectin® method, which includes a technology for gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with high efficiency.

BioNTech is allowed to use RetroNectin® for production of its cell & gene therapy products, therapies in which a patient’s T cells are genetically engineered to express a CAR for the treatment of multiple solid tumours.

The method is said to be one of the mostly used standard protocols utilised for “Engineered T-cell Therapy,” and Takara Bio is expecting higher sales growth following its recent worldwide promotional activities.

More information online